Use of GLP-1 weight-loss drugs in the U.S. has tripled since 2024.

The percentage of American adults who are currently taking a GLP-1 drug for weight loss is 11%, according to a new survey ...

The share of U.S. adults taking GLP-1 medications to lose weight has reached a record 11%. That's about 40 million people—as ...

First approved in 2021, the new weight loss drugs, “GLP-1 receptor agonists,” include several medications, notably semaglutide (Wegovy, Ozempic). The GLP-1s suppress appetite so well that they are the ...

Retatrutide is one of those drugs. It helped people lose a massive amount of weight in clinical trials. It also improved sleep apnea and knee pain. Wegovy is the first GLP-1 approved for weight loss, ...

For millions of people who have struggled with weight loss, a new experimental drug from Eli Lilly may present the most promising option yet. Today, the pharmaceutical company announced the results ...

Millions of Americans are expected to gain coverage for GLP-1 drugs for weight loss under a new U.S. pilot launching on ...

(ABC) — A new clinical trial from Eli Lilly and Company suggests its experimental triple hormone drug, retatrutide, could become one of the next major medications in the rapidly growing weight loss ...

Medicare previously covered GLP-1s only if the beneficiary also had a condition such as diabetes, sleep apnea, high blood ...

One of the most anticipated new weight-loss drugs also helped people struggling with common obesity-related conditions like sleep apnea. The drug is retatrutide, which pairs GLP-1, GIP and glucagon in ...